Flavia Borellini Acquires Shares of Revolution Medicines, Inc.
Flavia Borellini purchased 1,191 shares of Revolution Medicines on June 18, 2026.
Key Points
- Flavia Borellini bought 1,191 shares of Revolution Medicines, Inc. on June 18, 2026.
- Revolution Medicines, Inc. trades at $169.51 with a market cap of $35.25 billion.
- Analysts maintain a strong buy consensus with a target mean price of $187.29.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Flavia Borellini made a move on June 18, 2026, by purchasing 1,191 shares of Revolution Medicines, Inc. (NasdaqGS: RVMD). This insider transaction was not part of a pre-planned trading plan.
Insider Buying and Selling at Revolution Medicines, Inc.
On June 18, 2026, several insiders at Revolution Medicines, Inc. bought shares. Alongside Flavia Borellini's purchase of 1,191 shares, Kim Lorence, Sushil Patel, Frank Clyburn, and Elizabeth Anderson each acquired 3,127 shares. These transactions were not conducted under Rule 10b5-1 plans.
Revolution Medicines, Inc. Stock Down 18.5%
Shares of NasdaqGS:RVMD traded near $169.51 on Wednesday. Revolution Medicines, Inc. holds a market capitalization of approximately $35.25 billion. The company does not have a meaningful forward P/E ratio as it is not currently profitable. Its beta is 1.407, indicating higher volatility compared to the broader market. The stock's 52-week range spans from $34.00 to $166.84, with a 50-day moving average of $146.50 and a 200-day moving average of $95.18. Revolution Medicines maintains a strong liquidity position with a current ratio of 6.795 and a quick ratio of 6.589, alongside a debt-to-equity ratio of 29.153.
$RVMD stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On June 10, 2026, Evercore ISI Group maintained its buy rating on Revolution Medicines with a price target of $220. RBC Capital also maintained a buy rating, setting a target of $182 on June 2, 2026. HC Wainwright & Co. and Oppenheimer both maintained buy ratings with a $195 price target on June 1, 2026. Overall, the consensus among analysts is a strong buy, with a mean target price of $187.29 based on 21 analyst opinions.
About Revolution Medicines, Inc.
Revolution Medicines, Inc. is a biotechnology firm based in Redwood City, California. It focuses on developing targeted therapies for cancers driven by RAS mutations. The company's pipeline includes RAS(ON) inhibitors like daraxonrasib and elironrasib, which are in various stages of clinical development. Founded in 2014, Revolution Medicines is led by CEO Dr. Mark A. Goldsmith and employs about 883 people.
Bottom Line
Flavia Borellini's recent purchase of shares in Revolution Medicines, Inc. is part of broader insider activity at the company. Investors often track such insider transactions for potential insights into management's confidence. Revolution Medicines, Inc. remains a focus for analysts, with a strong buy consensus and a notable market presence in the biotechnology sector.
Get Revolution Medicines, Inc. alerts
New 13F filings, insider trades, and analyst moves on $RVMD, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.